Our R&D efforts are focused on bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent, as for NASH.
Our translational disease driven approach is the strength of our R&D. At Genfit, we believe in a full comprehension of a disease to discover therapeutic and diagnostic new solutions.
The rationale of our pipeline is to allow specialists physicians to change life of their patients thanks to our medicines.
GFT505 is Genfit’s lead pipeline product for the treatment of NASH (Non-Alcoholic Steato-Hepatitis), a recognized unmet medical need. GFT505 is currently being tested for clinical efficacy in NASH in a Phase 2b trial, one of the largest interventional studies ever conducted in NASH.
Boston, United States ->
San Diego, United States